In the coming year we should abandon interferons and glatiramer acetate as first line therapy for MS: No

Multiple Sclerosis Journal

Volumn 19, Issue 1, 2013, Pages 26-28

  Hillert, Jan ^a  

^a KAROLINSKA INSTITUTE   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA BETA INTERFERON RECEPTOR; BETA INTERFERON; FINGOLIMOD; FUMARIC ACID DIMETHYL ESTER; GLATIRAMER; INTERFERON CONSENSUS SEQUENCE BINDING PROTEIN; NATALIZUMAB; STAT3 PROTEIN;

ARTICLE; DISEASE ACTIVITY; DISEASE COURSE; DRUG EFFECT; DRUG EFFICACY; DRUG MEGADOSE; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; HUMAN; IMMUNOMODULATION; MULTIPLE SCLEROSIS; SIGNAL TRANSDUCTION; TREATMENT OUTCOME; UNSPECIFIED SIDE EFFECT;

EID: 84872299199     PISSN: 13524585     EISSN: 14770970     Source Type: Journal    
DOI: 10.1177/1352458512470312     Document Type: Article

References (15)

1. Polman CH, O'Connor P, Havrdova E, et al. A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis. N Engl J Med. 2006 ; 354: 899-910
2. Kappos L, Radue EW, O'Connor P, et al. A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis. N Engl J Med. 2010 ; 362: 387-401
3. Gold R, Kappos L, Arnold DL, et al. Placebo-controlled phase 3 study of oral BG-12 for relapsing multiple sclerosis. N Engl J Med. 2012 ; 367: 1098-1107
4. Jacobs LD, Cookfair DL, Rudick RA, et al. Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis. Ann Neurol. 1996 ; 39: 285-294
5. Randomised double-blind placebo-controlled study of interferon-1a in relapsing/remitting multiple sclerosis. Lancet. 1998 ; 352: 1498-1504
6. Miller DH, Soon D, Fernando KT, et al. MRI outcomes in a placebo-controlled trial of natalizumab in relapsing MS. Neurology. 2007 ; 68: 1390-1401
7. Li DK, Paty DW. Magnetic resonance imaging results of the PRISMS trial: a randomized, double-blind, placebo-controlled study of interferon-beta1a in relapsing-remitting multiple sclerosis. Prevention of Relapses and Disability by Interferon-beta1a Subcutaneously in Multiple Sclerosis. Ann Neurol. 1999 ; 46: 197-206
8. Comi G, Martinelli V, Rodegher M, et al. PreCISe study group. Effect of glatiramer acetate on conversion to clinically definite multiple sclerosis in patients with clinically isolated syndrome (PreCISe study): a randomised, double-blind, placebo-controlled trial. Lancet. 2009 ; 374: 1503-1511
9. Cohen JA, Barkhof F, Comi GC, et al. Oral fingolimod or intramuscular interferon for relapsing multiple sclerosis. N Engl J Med. 2010 ; 362: 402-415
10. Fox R, Miller DH, Phillips JT, et al. Placebo-controlled phase 3 study of oral BG-12 or glatiramer in multiple sclerosis. N Engl J Med. 2012 ; 367: 1087-1097
11. Shirani A, Zhao Y, Karim ME, et al. Association between use of interferon beta and progression of disability in patients with relapsing-remitting multiple sclerosis. JAMA. 2012 ; 308: 247-256
12. Trojano M, Pellegrini F, Fuiani A, et al. New natural history of interferon-treated relapsing multiple sclerosis. Ann Neurol. 2007 ; 61: 300-306
13. Tedeholm H, Lycke J, Skoog B, et al. Time to secondary progression in patients with multiple sclerosis who were treated with first generation immunomodulating drugs. Mult Scler J. 2012 ;:
14. Genetic risk and a primary role for cell-mediated immune mechanisms in multiple sclerosis. Nature. 2011 ; 476: 14-19
15. Havrdova E, Galetta S, Stefoski D, et al. Freedom from disease activity in multiple sclerosis. Neurology. 2010 ; 74: S3 - S7